TEMENOS
28.5.2020 08:32:10 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Banco Itaú (Suisse) SA and Banco Itaú International, affiliates belonging to one of the world’s largest private bank groups, Itaú Unibanco Holding SA (Itaú), have extended their relationship with Temenos to rapidly deploy Temenos Infinity Wealth and Temenos Transact on Temenos SaaS. Temenos’ cloud-native, cloud-agnostic, API-first technology will power the bank’s international private banking operations on a single, universal wealth management platform with rich functionality, spanning back-office processing through to front-office portfolio management. Temenos SaaS will provide a resilient, secure and fully compliant service to power Itaú’s private banking operations in Switzerland and the U.S. The shift to a single SaaS digital banking platform will drastically reduce the bank’s time-to-market, IT costs and operational complexity and achieve an improved cost/income ratio.
Temenos’ superior technology brings the benefits of SaaS, including accelerated and remote deployment, scalability and efficiencies, combined with elastic cost structure on cloud infrastructure.
Itaú Unibanco is the largest bank in Latin American, offering a broad range of retail, corporate, investment banking and asset management services for clients around the world. Itaú Unibanco has operations in 19 countries throughout the Americas, Europe and Asia. Temenos has been a partner of Itaú’s since 2017. Itaú Private Bank International has selected Temenos Infinity Wealth and Temenos Transact delivered by Temenos SaaS to gain synergies and efficiencies across its global operations by implementing a single digital wealth platform.
The agility, scalability and security of Temenos SaaS combined with the Temenos Model Bank approach provides pre-configured, country-specific functionality for the U.S. and Switzerland. Amid the ongoing COVID-19 pandemic, Temenos SaaS will enable Itaú Private Bank International to benefit from unrivalled levels of business resilience and security.
SaaS-powered Temenos Infinity Wealth, the leading omnichannel digital banking product, and Temenos Transact, the next generation in core banking, will drive operational efficiency throughout the business, allowing Itaú Private Bank International to free up resources formerly dedicated to IT infrastructure and focus on delivering seamless, digital customer experiences. The new digital platform will also support Itaú Private Bank International to increase its assets under management and customer base and scale its business in an agile and sustainable way. Temenos SaaS is continuously deployed 24X7, X365 days per year, delivering highly efficient, elastic scalability and automatically provisioning resources to perfectly match demand upwards or downwards.
Fernando Beyruti, Head of Itaú Private Bank International, said: “Investing in technology that can drive sustainable profitability, efficiency and client centricity is a key pillar of Itaú Private Bank International’s business strategy. With Temenos’ advanced, cloud-native technology, we will keep our attention and focus on the business. The rapid launch of our new, truly universal digital wealth platform supports our international operations and enables us to scale for global expansion in years to come.”
Max Chuard, Chief Executive Officer, Temenos, said: “We are excited to extend our partnership with Itaú, one of the largest banks in the world, as they embrace the power of the cloud to achieve operational excellence for their international private banking business. We are pioneers in cloud software and we have global banking expertise in rapidly deploying SaaS solutions in highly regulated environments. Temenos SaaS will provide Itaú Private Bank International with cost and scalability benefits, high security and availability. Temenos Infinity Wealth and Temenos Transact will transform Itaú Private Bank International’s entire business, from front to back office. Amid the global uncertainty surrounding the COVID-19 pandemic, Itaú Private Bank International will reap the benefits of a highly resilient and secure cloud offering, reduced time to market, and will be able to deliver outstanding digital customer experiences.”
– Ends –
About Itaú Unibanco Holding SA
Itaú Unibanco, with over 90 years of history, is the largest private bank in Latin America. Present in 19 countries in the Americas, Europe and Asia, it has more than 90 thousand employees and serves individual and corporate customers in all segments.
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005611/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom